Recurrent Central Nervous System Tumors
As with most other childhood malignancies, the reappearance of an intracranial tumor either locally or at distant sites after primary therapy implies a dire prognosis. However, retreatment may provide long subsequent survival or even cure of patients with recurrent biologically non-aggressive tumors such as pituitary adenoma, craniopharyngioma, meningioma, and cerebellar astrocytoma. Even the patient with a recurrent biologically aggressive tumor such as medulloblastoma may derive significant palliation and even cure from retreatment. Retreatment is more likely to be beneficial if administered when the recurrent tumor is still localized to a small volume and before apparent dissemination via the cerebral spinal fluid (CSF) pathways has occurred. Also, retreatment will be better tolerated if administered before deterioration in neurological status.
KeywordsAdenoma Oncol Methotrexate Neurol Hydrocephalus
Unable to display preview. Download preview PDF.
- 15.Bleyer W, Millstein J, Balais F, Pendergrass T, Chard R, Hartman J: 8 drugs in 1 day chemotherapy for brain tumors: A new approach and rationale for preradiation chemotherapy. Med Pediatr Oncol 11:213 (abstract), 1983.Google Scholar
- 22.Siegel T, Pfeffer MR, Catane R, Sulkes A, Gomori MJ, Fuks Z: Successful chemotherapy of recurrent intracranial germinoma with spinal metastases. Neurology 33:631–633, 1983.Google Scholar
- 28.Zeltzer PM: Chemotherapy for medulloblastoma: A review of treatment in recurrent and de novo tumors. In Zeltzer PM, Pochedly C (eds), Medulloblastoma in Children. New Concepts in Tumor Biology, Diagnosis and Treatment. New York: Praeger, 1986, pp 182–199.Google Scholar
- 29.Allen JC: Systemic metastases from medulloblastoma: Response to chemotherapy. In Zeltzer PM, Pochedly C (eds), New Concepts in Tumor Biology, Diagnosis and Treatment. New York: Praeger, 1986, pp 200–212.Google Scholar